-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Na + - glucose cotransporter (the SGLT) inhibitors can reduce cardiac blood vessel end; however, their effect on atrial fibrillation / atrial flutter (AF) remains unclear
.
Recently, a research article was published in JAHA, an authoritative journal in the field of cardiovascular diseases.
Researchers aim to determine whether SGLT inhibitors reduce AF and whether the history of AF will change the effect of SGLT inhibitors on the composite outcome of heart failure hospitalization or cardiovascular death
.
The researchers searched databases such as MEDLINE, Embase and CENTRAL, and the search time ended in March 2021
.
Two reviewers identified randomized controlled trials comparing SGLT inhibitors with placebo or no treatment
Thirty-one eligible trials reported AF events (75,279 participants, average age 62 years, 35.
0% were women)
.
Moderate quality evidence supports that SGLT inhibitors can reduce the risk of serious AF events (1.
SGLT inhibitors can reduce AF events and may reduce the risk of heart failure hospitalization/cardiovascular death to a similar degree in patients with and without AF
Original source:
Arjun K.
Pandey.
et al.
Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials .
JAHA.
Sodium-Glucose Co-Transporter Inhibitors and Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials in this message
